Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Rev. Assoc. Med. Bras. (1992) ; 67(supl.1): 86-90, 2021. graf
Article Dans Anglais | LILACS | ID: biblio-1287865

Résumé

SUMMARY OBJECTIVE: This article aims to alert health professionals for cancer screening in the face of the possibility of new waves of disease. METHODS: A narrative review was conducted through a search in MEDLINE, Lilacs, Chinese Biomedical Literature Database, and international medical societies publications. RESULTS: Breast cancer: in high-risk patients (confirmed familial cancer syndrome or with high-risk tools scores), clinicians should act according to usual recommendations; in average-risk individuals, consider screening with mammography with a longer time span (maximum of two years). Cervical cancer: women turning 25 years old who have already been immunized and with no previous Pap test can have the test postponed during the pandemic; if there is no previous dose of Human Papillomavirus vaccination, initiation of screening should be recommended following a more rigid approach for COVID prevention; in women over 30 years of age who have never participated in cervical screening, the first screening exam is also essential. Colorectal cancer: if the individual is at elevated risk for familial cancer, the screening with colonoscopy according to usual recommendations should be supported; if at average risk consider screening with Fecal Occult Blood Test. Prostate cancer: there is a trend to postpone routine prostate cancer screening until the pandemic subsides. CONCLUSIONS: The decision to keep cancer screening must be discussed and individualized, considering the possibility of new waves of COVID-19.


Sujets)
Humains , Mâle , Femelle , Adulte , Tumeurs de la prostate , Tumeurs colorectales , Tumeurs du col de l'utérus/diagnostic , Tumeurs du col de l'utérus/prévention et contrôle , Infections à papillomavirus , Vaccins contre les papillomavirus , COVID-19 , Dépistage de masse , Antigène spécifique de la prostate , Dépistage précoce du cancer , SARS-CoV-2
SÉLECTION CITATIONS
Détails de la recherche